Dr. Shane Johnson, SVP and GM of BayMedica, InMed’s subsidiary, joins Benzinga’s All Access Conference on June 17, 2022.

Dr. Johnson talks about how manufacturing techniques used to produce many pharmaceutical products such as biosynthesis can be used produce bioidentical rare cannabinoids that provide the consistency and purity needed to supply the health and wellness sector. He talks about the recent launch of several rare cannabinoids such as delta-9 THCV and CBDV.

Read full article here.